Rocket Pharmaceuticals received the rare pediatric disease priority review voucher with the accelerated FDA approval for Kresladi in March. The non-dilutive capital from the voucher’s sale will support a pipeline that includes a gene therapy in pivotal clinical testing for the rare genetic disorder Danon disease.
The post Rocket Pharma Reaps $180M From Sale of FDA Drug Review Fast Pass appeared first on MedCity News.
